• Explore /
  • Poster
  • / Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.

Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.

Abstract Poster

Authors

null

Daniel Taussky

Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal University, Montreal, QC, Canada

Daniel Taussky , Julie Piotte , Kevin Zorn , Marc Zanaty , Vimal Krishnan , Jean-Paul Bahary , Marie-Claude Beauchemin , Maroie Barkati , Cynthia Menard , Guila Delouya , Carole Lambert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 96)

DOI

10.1200/JCO.2017.35.6_suppl.96

Abstract #

96

Poster Bd #

E7

Abstract Disclosures

Similar Posters

First Author: Domenique Escobar

First Author: Tamim Niazi

First Author: Yutaka Hashimoto

First Author: Carole Helissey